US4782062A
Expired / Lapsed
US
⏱️ 0.0 years remaining
9-(2-hydroxymethyl)cycloalkylmethyl) guanines
Assignee: Merck and Co Inc
•
Filing: 1987-05-11
•
Granted: 1988-11-01
•
Expires: 2007-05-11
Abstract
Abstract 9-[2-(Hydroxymethyl)cycloalkylmethyl]guanines which are herpes simplex viral thymidine kinase inhibitors, their acyl derivatives, their phosphate derivatives and their pharmaceutically-acceptable salts; pharmaceutical formulations containing these compounds; the treatment of DNA viral, particularly herpes viral, infections with these compounds; methods of preparing these compounds; and novel intermediates useful in their preparation.
Inventors
- 👤 Richard L. Tolman
- 👤 John D. Karkas
- 👤 Wallace T. Ashton
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 20:51
CPC Classifications
C; C07; C07D; C07D473/00; A; A61; A61P; A61P31/00; A61P31/12
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
51 words
A 9-[2-(hydroxymethyl)cycloalkylmethyl]-8-substituted-guanine of the formula: ##STR5## wherein R is H, halogen, C 1 -C 4 -straight or branched-chain alkyl; n is 2 to 6; and R 2 is H or ##STR6## wherein R 1 is C 1 -C 12 -straight or branched-chain alkyl, phenyl or naphthyl, or a pharmaceutically-acceptable salt thereof.
Claim 2
Dependent Claim
51 words
A 9-[2-(hydroxymethyl)cycloalkylmethyl]-8-substituted-guanine of the formula: ##STR5## wherein R is H, halogen, C 1 -C 4 -straight or branched-chain alkyl; n is 2 to 6; and R 2 is H or ##STR6## wherein R 1 is C 1 -C 12 -straight or branched-chain alkyl, phenyl or naphthyl, or a pharmaceutically-acceptable salt thereof.
Claim 3
Dependent Claim
18 words
A 9-[2-(hydroxymethyl)cycloalkylmethyl]-8-substituted-guanine according to claim 1, which is 9-[(Z)-2-(hydroxymethyl)cyclobutylmethyl]guanine; 9-[(Z)-2-(hydroxymethyl)cyclopentylmethyl]guanine; 9-[(Z)-2-(hydroxymethyl)cyclohexylmethyl]guanine; 9-[(E)-2-(hydroxymethyl)cyclohexylmethyl]guanine; 9-[(Z)-2-(hydroxymethyl)cycloheptylmethyl]guanine; 9-[(Z)-2-(hydroxymethyl)cyclooctylmethyl]guanine; 9-[(Z)-2-(propionyloxymethyl)cyclohexylmethyl]guanine; 9-[(Z)-2-(benzyloxymethyl)cyclohexylmethyl]guanine; or 9-[(Z)-2-(acetoxymethyl)cyclohexylmethyl]guanine.
Claim 4
Dependent Claim
12 words
A 9-[2-(hydroxymethyl)cycloalkylmethyl]-8-substituted-guanine according to claim 2, which is 9-[(Z)-2-(hydroxymethyl)cyclohexylmethyl]guanine; 9-[(Z)-2-(hydroxymethyl)cyclobutylmethyl]guanine; or 9-[(Z)-2-(hydroxymethyl)cyclopentylmethyl]guanine.
Claim 5
Dependent Claim
23 words
A composition useful for imparting viral thymidine kinase-inhibiting activity comprising a carrier and a therapeutically-effective amount of a 9-[2-(hydroxymethyl)cycloalkylmethyl]-8-substituted-guanine according to claim 1.
Claim 6
Dependent Claim
25 words
A method of inhibiting viral thymidine kinase activity in mammalian or avian species comprising administering a therapeutically-effective amount of a 9-[2-(hydroxymethyl)cycloalkylmethyl]-8-substituted-guanine according to claim 1.
Claim 7
Dependent Claim
53 words
A method according to claim 5, wherein the viral thymidine kinase activity is a herpes viral thymidine kinase activity, the therapeutically-effective amount is from 0.01 to about 200 mg/kg of body weight/day, the mammalian or avian species is a human being, and the guanine according to claim 1 is 9-[(Z)-2-(hydroxymethyl)cyclohexylmethyl]guanine; 9-[(Z)-2-(hydroxymethyl)cyclobutylmethyl]guanine; or 9-[(Z)-2-(hydroxymethyl)cyclopentylmethyl]guanine.
References Cited (Backward Citations)
US4617304A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-11-01 | 1992-05-02 | 1992-11-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-11-01 | 1996-05-02 | 1996-11-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-11-01 | 2000-05-02 | 2000-11-01 | $7700.00 | Window Closed / Lapsed |